OBJECTIVE: To determine the amount of growth in vestibular schwannomas in Neurofibromatosis type 2 (NF2) patients from diagnosis through short-term (up to 2 yr) and long-term (up to 4 yr) follow-up. STUDY DESIGN: Retrospective magnetic resonance imaging (MRI) films were obtained on subjects enrolled in the NF2 Natural History study and examined for changes in vestibular schwannoma size over time. SETTING: Data were collected from nine foreign and domestic NF2 centers, including hospital-based, academic, and tertiary care centers. SUBJECTS: NF2 patients with MRI data and at least one follow-up examination within 9 months to 2 years of diagnosis were included; n=56 patients with 84 lesions for evaluation of growth. INTERVENTION: Routine, clinically obtained, magnetic resonance images were digitized and measured using image management software. Short-term follow-up was defined as up to 2 years (n=84 lesions), and long-term follow-up was defined as 3 to 4 years (n=29 lesions). OUTCOME MEASURES: Vestibular schwannoma size was assessed using anterior-posterior, medial-lateral, and greatest diameter linear measurements. RESULTS: Vestibular schwannomas increased in size (at least 5 mm) in 8% of the vestibular schwannomas across short-term follow-up. At long-term follow-up, 13% of the tumors had increased in size. On average, schwannomas increased in greatest diameter 1.3 mm per year across short-term follow-up. CONCLUSION: Slightly greater than 1 in 10 diagnosed NF2-related vestibular schwannomas increased in size by at least 5 mm by 4 years of follow-up, if still untreated at that time.
OBJECTIVE: To determine the amount of growth in vestibular schwannomas in Neurofibromatosis type 2 (NF2) patients from diagnosis through short-term (up to 2 yr) and long-term (up to 4 yr) follow-up. STUDY DESIGN: Retrospective magnetic resonance imaging (MRI) films were obtained on subjects enrolled in the NF2 Natural History study and examined for changes in vestibular schwannoma size over time. SETTING: Data were collected from nine foreign and domestic NF2 centers, including hospital-based, academic, and tertiary care centers. SUBJECTS:NF2patients with MRI data and at least one follow-up examination within 9 months to 2 years of diagnosis were included; n=56 patients with 84 lesions for evaluation of growth. INTERVENTION: Routine, clinically obtained, magnetic resonance images were digitized and measured using image management software. Short-term follow-up was defined as up to 2 years (n=84 lesions), and long-term follow-up was defined as 3 to 4 years (n=29 lesions). OUTCOME MEASURES: Vestibular schwannoma size was assessed using anterior-posterior, medial-lateral, and greatest diameter linear measurements. RESULTS:Vestibular schwannomas increased in size (at least 5 mm) in 8% of the vestibular schwannomas across short-term follow-up. At long-term follow-up, 13% of the tumors had increased in size. On average, schwannomas increased in greatest diameter 1.3 mm per year across short-term follow-up. CONCLUSION: Slightly greater than 1 in 10 diagnosed NF2-related vestibular schwannomas increased in size by at least 5 mm by 4 years of follow-up, if still untreated at that time.
Authors: Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini Journal: Am J Med Genet A Date: 2011-12-02 Impact factor: 2.802
Authors: Michael S Dirks; John A Butman; H Jeffrey Kim; Tianxia Wu; Keaton Morgan; Anne P Tran; Russell R Lonser; Ashok R Asthagiri Journal: J Neurosurg Date: 2012-04-13 Impact factor: 5.115
Authors: Ramita Dewan; Alex Pemov; H Jeffrey Kim; Keaton L Morgan; Raul A Vasquez; Prashant Chittiboina; Xiang Wang; Settara C Chandrasekharappa; Abhik Ray-Chaudhury; John A Butman; Douglas R Stewart; Ashok R Asthagiri Journal: Neuro Oncol Date: 2014-12-01 Impact factor: 12.300
Authors: Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Filippo G Giancotti; Alexander Filatov; Anna Derman; Tsivia Hochman; Judith D Goldberg; Emilio Vega; Jeffrey H Wisoff; John G Golfinos; Amanda Merkelson; J Thomas Roland; Jeffrey C Allen Journal: Neuro Oncol Date: 2013-12-04 Impact factor: 12.300